News & Updates
Filter by Specialty:
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
26 Oct 2021Therapeutic heparin may reduce death, bleeding risks in moderate COVID-19
Use of therapeutic heparin does not appear to significantly reduce the death, mechanical ventilation, or intensive care unit (ICU) admission in hospitalized patients with moderate COVID-19 and increased D-dimer levels, reveals a study. However, it is associated with a significantly lower chances of all-cause death and reduced risk of major bleeding.
Therapeutic heparin may reduce death, bleeding risks in moderate COVID-19
26 Oct 2021Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer
The risk of disease recurrence is increased among rectal cancer patients treated with dose-capped chemoradiotherapy (CRT), reveals a study. In addition, excessive toxicity has occurred among those dosed by actual body surface area (BSA) compared to patients in the dose-capped group.
Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer
24 Oct 2021Prompt antibiotic treatment prevents surgery in preseptal, orbital cellulitis
Differential diagnosis of preseptal and orbital cellulitis show “extremely sensitive” clinical presentation and C-reactive protein (CRP), according to a study, noting that prompt initiation of intravenous antibiotics is required and helps prevent surgical procedures even in those with incipient abscesses.